title: In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells.
abstract: Granulocyte-macrophage colony-stimulating factor, (GM-CSF) was given at 8 micrograms/kg daily by continuous i.v. infusion for 72 h to six patients with acute myeloid leukemia (AML) in expansion and one with chronic myeloid leukemia in blastic crisis to determine whether it was possible to augment the proliferative activity of the neoplastic population. The percentage of marrow blasts in S phase (labeling index, LI) was increased in five patients (1.3-, 1.5-, 1.9-, 2.3- and 3.2-fold change). The increase in LI was similar 24 and 48 h after beginning GM-CSF. The RNA Index also increased in patients who showed an increased LI, suggesting that GM-CSF had recruited quiescent neoplastic cells into the cell cycle. Forty eight hours after beginning GM-CSF, chemotherapy was started. The fate of S phase cells, labeled in vivo with bromodeoxyuridine (BrdU) immediately before cytostatic treatment, was monitored. BrdU positive cells were identified by fluorescent antibody for up to 28 days. A preferential killing of BrdU (S phase) cells was observed in 5/7 patients who obtained a complete remission, whereas this was not apparent in the two patients who achieved only a partial remission. Chemotherapy induced a rapid and profound aplasia; its duration, however, was not significantly different from that observed in historical controls. GM-CSF may have a potential role in the treatment of AML, as this study shows that it recruits leukemic cells into the cell cycle without adversely prolonging aplasia after cycle-specific therapy.
authors.affiliation: Clinica Medica, Dipartimento di Scienze Biomediche ed Oncologia Umana, Università di Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Aglietta
authors.forename: L
authors.initials: L
authors.lastname: De Felice
authors.forename: A
authors.initials: A
authors.lastname: Stacchini
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
authors.forename: A C
authors.initials: AC
authors.lastname: Bianchi
authors.forename: M A
authors.initials: MA
authors.lastname: Aloe Spiriti
authors.forename: F
authors.initials: F
authors.lastname: Sanavio
authors.forename: F
authors.initials: F
authors.lastname: Apra
authors.forename: W
authors.initials: W
authors.lastname: Piacibello
authors.forename: A C
authors.initials: AC
authors.lastname: Stern
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001973:Bromodeoxyuridine; D002453:Cell Cycle / Q000187:drug effects; D005260:Female; D005455:Fluorescent Antibody Technique; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D012074:Remission Induction
chemical_list: D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D001973:Bromodeoxyuridine